enGene Holdings Inc.

NASDAQ:ENGN

Biotechnology

Healthcare
$1.85 -1.15%

-$0.02 today

Market cap
$123.98M
Beta
-0.29
P/E (TTM)
-1.8
EPS (TTM)
-$0.95
52W Low $1.40High $12.25

Volume 2.81M

Average 1.58M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$99.24M

FY 2025 · Annual

Investing Cash Flow

-$25.14M

FY 2025 · Annual

Financing Cash Flow

$1.52M

FY 2025 · Annual

-99.4% YoY

Cash Flow Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Net Income(23.44M)(24.46M)(99.92M)(55.14M)(117.3M)
Depreciation & Amortization272K238K175K323K509K
Deferred Income Tax00000
Stock-Based Compensation435K116K3.45M5.32M9.65M
Change in Working Capital(1.04M)2.17M(517K)95K9.74M
Accounts Receivables295K143K(1.01M)2.01M(595K)
Inventory00000
Accounts Payables110K(197K)373K474K4.94M
Other Working Capital(1.44M)2.23M117K(2.39M)5.39M
Other Non-Cash Items7.79M4.34M72.07M1.12M(1.83M)
Operating Cash Flow(15.98M)(17.59M)(24.74M)(48.28M)(99.24M)
Capital Expenditures(248K)(153K)(318K)(925K)(1.49M)
Acquisitions (Net)00000
Purchases of Investments000(125.03M)(160.84M)
Sales of Investments0000137.19M
Other Investing Activities1K0000
Investing Cash Flow(247K)(153K)(318K)(125.95M)(25.14M)
Debt Repayment7.07M28.39M33.27M13.06M(699K)
Common Stock Issued14K12K56.89M260.15M2.22M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(144K)(423K)(4.01M)(7.49M)0
Financing Cash Flow22.53M27.97M86.15M265.72M1.52M
Effect of Forex Changes98K(805K)1K1K1K
Net Change in Cash6.39M9.42M61.09M91.48M(122.85M)
Free Cash Flow(16.23M)(17.75M)(25.06M)(49.21M)(100.72M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$117.3M
+ D&A$509.0K
+ Stock-Based Comp$9.6M
+ Deferred Tax$0
+ Working Capital$9.7M
- Other Non-Cash-$1.8M
= Operating Cash Flow-$99.2M
- Capex-$1.5M
= Free Cash Flow-$100.7M

Analysis

FY2025 free cash flow is -$100.7M. FCF conversion is 85.9% of net income. Operating cash flow was -$99.2M, with capex of -$1.5M. The largest bridge item is Working Capital at $9.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
3Initial statement of beneficial ownershipNov 13, 2026
SC 13GSC 13G filingNov 13, 2026
8-KCurrent reportNov 12, 2026
4Statement of changes in beneficial ownershipSep 24, 2026

Does ENGN generate free cash flow?

enGene Holdings Inc. (ENGN) generated -$100.72M of free cash flow in fiscal 2025.

How much operating cash flow does ENGN produce?

Operating cash flow was -$99.24M, before capital expenditures of $1.49M.